The call conveyed a broadly positive tone driven by robust revenue growth (44% FY), first full-year net income, strong adjusted EBITDA ($59.4M), high gross margins (85%+), a strengthened balance sheet and ambitious 2026 guidance (>30% growth midpoint). Management is investing meaningfully in commercial expansion and a high-value pipeline asset (XP-8121) with planned R&D and SG&A step-ups to support future growth. Primary risks highlighted include newly filed Recorlev patent litigation with uncertain timelines, concentration of growth in Recorlev, and near-term increases in R&D and SG&A expenditures that will be absorbed to enable longer-term upside.

Company Guidance

Xeris guided full‑year 2026 total revenue of $375M–$390M (which represents more than 30% growth at the midpoint versus 2025 total revenue of $291.8M and Q4 revenue of $85.8M), said it will remain adjusted‑EBITDA positive and that adjusted‑EBITDA will grow in absolute dollars versus 2025’s $59.4M, expects a modest improvement in gross margin versus 2025 (FY gross margin 85%, Q4 87%) with gross‑to‑net broadly steady, plans to step up R&D by approximately $25M to support initiation of the XP‑8121 Phase III in H2 2026 (2025 R&D was $31.2M), will increase SG&A by roughly $45M to fund a near‑doubling of the commercial footprint (2025 SG&A was $182.4M), expects partnerships/other revenue to remain in the historical ~5–10% range, and highlighted product metrics (Recorlev ~700 patients and $139.3M FY revenue, >100% growth; Gvoke $94.1M FY, ~14% growth; Keveyis $47.6M FY) along with long‑term peak sales assumptions of $1B for Recorlev by 2035 and $1–3B potential peak sales for XP‑8121.

Strong Top-Line Growth

Total revenue for FY2025 was $291.8M, an increase of 44% year-over-year; Q4 revenue was $85.8M, up 43% year-over-year.

Recorlev Outperformance

Recorlev revenue was $45.3M in Q4 and $139.3M for FY2025, growing more than 100% for both the quarter and full year; patient base ended 2025 at ~700 patients, nearly double year-end 2024.

Durable Contributions from Gvoke and Keveyis

Gvoke generated $24.6M in Q4 and $94.1M for FY2025 (full-year growth of 14%), providing steady, predictable revenue. Keveyis produced $12.8M in Q4 and $47.6M for FY2025 and increased the average number of patients on therapy.

First Full-Year Net Income and Positive Adjusted EBITDA

Company delivered net income for the full year 2025 and adjusted EBITDA of $59.4M for FY2025 (Q4 adjusted EBITDA $25.1M, an improvement of $16.8M year-over-year).

High and Improving Gross Margins

Gross margin was 87% in Q4 and 85% for FY2025, reflecting improvement versus prior year driven by favorable product mix.

Financial Self-Sustainability and Strong Balance Sheet

Management stated the company reached financial self-sustainability in 2025, with an improved balance sheet that provides flexibility to fund growth, advance XP-8121, and support commercial investments.

Ambitious 2026 Guidance

2026 revenue guidance of $375M to $390M (midpoint implying >30% growth versus 2025) with expectation to remain adjusted EBITDA positive and to grow adjusted EBITDA in absolute dollars versus 2025.

Progressing High-Value Pipeline Asset: XP-8121

XP-8121 is on track to initiate Phase III in H2 2026; company projects potential peak sales of $1B–$3B. Management estimates 20M hypothyroid patients on oral therapy with 3M–5M potentially unable to maintain normal ranges due to GI absorption, representing the target opportunity.

Commercial Investment to Drive Future Growth

Recorlev commercial team nearly doubled in January 2026 (sales, patient support, medical affairs, pharmacy services) to accelerate awareness and adoption, with management expecting impact to be notable in H2 2026 and beyond.

Intellectual Property Protection for Recorlev

Company filed a patent infringement lawsuit against two ANDA filers and cites four Orange Book-listed patents for Recorlev that extend to March 2040 plus orphan drug exclusivity through end of 2028.

Xeris Pharmaceuticals (XERS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XERS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 07, 2026	2026 (Q1)	<0.01 / -	-0.06	―	―	―
Mar 02, 2026	2025 (Q4)	0.02 / 0.06	-0.03	300.00% (+0.09)	―
Nov 06, 2025	2025 (Q3)	<0.01 / 0.00	-0.11	―	―
Aug 07, 2025	2025 (Q2)	-0.03 / -0.01	-0.1	90.00% (+0.09)	―
May 08, 2025	2025 (Q1)	-0.05 / -0.06	-0.14	57.14% (+0.08)	―
Mar 06, 2025	2024 (Q4)	-0.06 / -0.03	-0.1	70.00% (+0.07)	―
Nov 08, 2024	2024 (Q3)	-0.09 / -0.11	-0.09	-22.22% (-0.02)	―
Aug 08, 2024	2024 (Q2)	-0.10 / -0.10	-0.14	28.57% (+0.04)	―
May 09, 2024	2024 (Q1)	-0.11 / -0.14	-0.12	-16.67% (-0.02)	―
Mar 06, 2024	2023 (Q4)	-0.09 / -0.10	-0.1	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XERS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 02, 2026	$6.12	$6.02	-1.63%
Nov 06, 2025	$9.87	$7.71	-21.88%
Aug 07, 2025	$5.49	$6.60	+20.22%
May 08, 2025	$4.48	$5.16	+15.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xeris Pharmaceuticals (XERS) report earnings?

Xeris Pharmaceuticals (XERS) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).

What is Xeris Pharmaceuticals (XERS) earnings time?

Xeris Pharmaceuticals (XERS) earnings time is at May 07, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XERS EPS forecast?

XERS EPS forecast for the fiscal quarter 2026 (Q1) is <0.01.